S. Smesny

发表

Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test – a fMRI study

H. Sauer, S. Riehemann, H. Volz, 2001, European Archives of Psychiatry and Clinical Neuroscience.

Effects of Lorazepam on the Neuromagnetic Mismatch Negativity (MMNm) and Auditory Evoked Field Component N100m

H. Sauer, S. Smesny, T. Rosburg, 2004, Neuropsychopharmacology.

Hippocampal Structure, Metabolism, and Inflammatory Response after a 6-Week Intense Aerobic Exercise in Healthy Young Adults: A Controlled Trial

Marco Herbsleb, Christian Puta, Karl-Jürgen Bär, 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Thalamocortical connectivity during resting state in schizophrenia

Otto W. Witte, Heinrich Sauer, Igor Nenadic, 2014, European Archives of Psychiatry and Clinical Neuroscience.

Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

Meredith J. McHugh, I. Hickie, S. Smesny, 2017, Psychotherapy and Psychosomatics.

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

I. Hickie, S. Smesny, M. Nordentoft, 2020, Schizophrenia Research.

Dynamic prediction of transition to psychosis using joint modelling

A. Mackinnon, I. Hickie, S. Smesny, 2018, Schizophrenia Research.

Aging effects on regional brain structural changes in schizophrenia.

H. Sauer, S. Smesny, Christian Gaser, 2012, Schizophrenia bulletin.

Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials

D. Wishart, S. Smesny, Anchi Guo, 2022, Pharmacological Reviews.

Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?

S. Smesny, P. McGorry, M. Cannon, 2016, BMC Psychiatry.

Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis.

H. Sauer, S. Smesny, M. Berk, 2015, Prostaglandins, leukotrienes, and essential fatty acids.

Prefrontal gyrification in psychotic bipolar I disorder vs. schizophrenia.

H. Sauer, S. Smesny, Christian Gaser, 2015, Journal of affective disorders.

Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study

S. Smesny, M. Berk, C. Davey, 2017, Translational Psychiatry.

I. Hickie, S. Smesny, M. Nordentoft, 2020, Schizophrenia bulletin.

Title:Prediction of clinical outcomes beyondpsychosis in the Ultra-High Risk for psychosis population

Swapna, S. Smesny, M. Nordentoft, 2020 .

Relapse Prevention Intervention after Suicidal Event (RISE): Feasibility study of a psychotherapeutic short-term program for inpatients after a recent suicide attempt

G. Wagner, S. Smesny, T. Sobanski, 2022, Frontiers in Psychiatry.

Polyunsaturated fatty acids in emerging psychosis: a safer alternative?

S. Smesny, P. Fusar-Poli, P. McGorry, 2014, Early intervention in psychiatry.

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

I. Hickie, G. Cagney, S. Smesny, 2022, Translational Psychiatry.

Fluorometric Assays of Phospholipase A2 Activity with Three Different Substrates in Biological Samples of Patients with Schizophrenia

H. Sauer, S. Smesny, D. Kinder, 2003, Clinical chemistry and laboratory medicine.

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

I. Hickie, S. Smesny, M. Nordentoft, 2019, Front. Psychiatry.

Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial

I. Hickie, S. Smesny, R. Hester, 2022, BJPsych Open.

Reduced phosphodiesters and high-energy phosphates in the frontal lobe of neuroleptic-free schizophrenic patients — a 31P-chemical shift spectroscopic-imaging study

S. Smesny, R. Rzanny, J. Czekalla, 2000, European Neuropsychopharmacology.

Disturbed glutathione antioxidative defense is associated with structural brain changes in neuroleptic-naïve first-episode psychosis patients.

J. Reichenbach, G. Wagner, S. Smesny, 2017, Prostaglandins, leukotrienes, and essential fatty acids.

ZNF804A genetic variation (rs1344706) affects brain grey but not white matter in schizophrenia and healthy subjects

S. Cichon, M. Nöthen, R. Schlösser, 2014, Psychological Medicine.

Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia.

H. Sauer, S. Smesny, T. Rosburg, 2005, Prostaglandins, leukotrienes, and essential fatty acids.

The influence of age and gender on niacin skin test results - implications for the use as a biochemical marker in schizophrenia.

H. Sauer, S. Smesny, T. Rosburg, 2004, Journal of psychiatric research.

Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia

Timm Rosburg, Hans-Peter Volz, Heinrich Sauer, 2007, NeuroImage.

Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a 31P chemical shift spectroscopic-imaging study

H. Sauer, S. Riehemann, H. Volz, 2000, Biological Psychiatry.

Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study

S. Smesny, M. Berk, Sung-Wan Kim, 2016, PloS one.

Glutamate receptor δ 1 (GRID1) genetic variation and brain structure in schizophrenia.

Thomas W. Mühleisen, S. Cichon, T. Mühleisen, 2012, Journal of psychiatric research.

Machine learning based prediction and the influence of complement – Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial

I. Hickie, G. Cagney, S. Smesny, 2022, Brain, Behavior, and Immunity.

Classification of first-episode psychosis using cortical thickness: A large multicenter MRI study

R. Murray, F. Piras, G. Spalletta, 2021, European Neuropsychopharmacology.

Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers

S. Smesny, B. Baune, P. McGorry, 2016, Translational psychiatry.

Organic bipolar disorder occurring together with spontaneous intracranial hypotension

O. Witte, S. Smesny, H. Axer, 2004, Psychiatry Research: Neuroimaging.

Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients

J. Reichenbach, H. Sauer, S. Smesny, 2015, Schizophrenia Research.

Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis – Results of the randomized controlled Vienna omega-3 study

H. Sauer, S. Smesny, P. McGorry, 2017, Schizophrenia Research.

Default mode network activity in schizophrenia studied at resting state using probabilistic ICA

Christian Gaser, Jürgen R. Reichenbach, Heinrich Sauer, 2012, Schizophrenia Research.

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

I. Hickie, S. Smesny, M. Nordentoft, 2019, Schizophrenia Research.

State marker properties of niacin skin sensitivity in ultra-high risk groups for psychosis - An optical reflection spectroscopy study

H. Sauer, S. Smesny, M. Berger, 2017, Schizophrenia Research.

Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis

H. Sauer, S. Smesny, M. Berk, 2016, PloS one.

Potential use of the topical niacin skin test in early psychosis -- a combined approach using optical reflection spectroscopy and a descriptive rating scale.

H. Sauer, S. Riehemann, S. Smesny, 2003, Journal of psychiatric research.

Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population

S. Smesny, M. Nordentoft, A. Riecher-Rössler, 2020, Early intervention in psychiatry.

Neurometabolic patterns of an “at risk for mental disorders” syndrome involve abnormalities in the thalamus and anterior midcingulate cortex

J. Reichenbach, G. Wagner, S. Smesny, 2020, Schizophrenia Research.

Alterations of neurometabolism in the dorsolateral prefrontal cortex and thalamus in transition to psychosis patients change under treatment as usual – A two years follow-up 1H/31P-MR-spectroscopy study

J. Reichenbach, S. Smesny, M. Walther, 2021, Schizophrenia Research.

Polyunsaturated fatty acid biostatus, phospholipase A2 activity and brain white matter microstructure across adolescence

P. DeRosse, A. Malhotra, P. Szeszko, 2017, Neuroscience.

The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial

I. Hickie, S. Smesny, M. Nordentoft, 2021, Brain, Behavior, and Immunity.

Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes

I. Hickie, S. Smesny, M. Nordentoft, 2019, Schizophrenia Research.

The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo

I. Hickie, S. Smesny, M. Nordentoft, 2017, Schizophrenia Research.

Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis

H. Sauer, S. Smesny, I. Nenadić, 2014, Molecular Psychiatry.

Antipsychotic drug effects on left prefrontal phospholipid metabolism: A follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients

H. Sauer, S. Smesny, J. Reichenbach, 2012, Schizophrenia Research.

NEURAPRO‐E study protocol: a multicentre randomized controlled trial of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders

I. Hickie, S. Smesny, M. Nordentoft, 2017, Early intervention in psychiatry.

Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism.

R. Neubert, H. Sauer, S. Smesny, 2013, Schizophrenia bulletin.

Cannabinoids Influence Lipid–Arachidonic Acid Pathways in Schizophrenia

H. Sauer, S. Smesny, T. Rosburg, 2007, Neuropsychopharmacology.

Serum S100B Protein is Specifically Related to White Matter Changes in Schizophrenia

H. Sauer, S. Smesny, Christian Gaser, 2016, Front. Cell. Neurosci..

Altered Prostaglandin Mediated Skin Flush in Schizophrenia–Implications for Early Psychosis Interventions

H. Sauer, S. Smesny, T. Rosburg, 2003 .

Pronounced immunological abnormalities in unmedicated first episode as compared to chronic schizophrenia patients

S. Smesny, P. Elsner, U. Hipler, 2019 .

Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis

I. Hickie, S. Smesny, R. Hester, 2020, Early intervention in psychiatry.

Long-Chain Omega-3 Fatty Acids and Psychotic Disorders

S. Smesny, P. Fusar-Poli, P. McGorry, 2013 .

Alterations of niacin skin sensitivity in recurrent unipolar depressive disorder.

H. Sauer, S. Smesny, I. Nenadić, 2010, Journal of affective disorders.

Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial.

I. Hickie, S. Smesny, M. Nordentoft, 2019, Behaviour research and therapy.

Predictors of longer-term outcome in the Vienna omega-3 high-risk study

S. Smesny, P. McGorry, N. Mossaheb, 2017, Schizophrenia Research.

Bioactive lipids in schizophrenia

S. Smesny, G. Amminger, G. Amminger, 2006, International review of psychiatry.

Brain structure in people at ultra-high risk of psychosis, patients with first-episode schizophrenia, and healthy controls: a VBM study

J. Reichenbach, H. Sauer, S. Smesny, 2015, Schizophrenia Research.

Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia

H. Sauer, S. Smesny, J. Lasch, 2008, Journal of Neural Transmission.

Prefrontal glutamatergic emotion regulation is disturbed in cluster B and C personality disorders - A combined 1H/31P-MR spectroscopic study.

J. Reichenbach, G. Wagner, S. Smesny, 2018, Journal of affective disorders.

Auditory hallucinations and brain structure in schizophrenia: voxel-based morphometric study

Christian Gaser, Heinrich Sauer, Igor Nenadic, 2010, British Journal of Psychiatry.

[Modern follow-up strategies for the treatment of patients with superficial bladder carcinoma].

S. Smesny, J. Schubert, W. Werner, 2000, Zeitschrift fur arztliche Fortbildung und Qualitatssicherung.

Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing

D. Van De Ville, C. Sandini, D. Zoller, 2020, medRxiv.

Brain Derived Neurotrophic Factor Deficiency is Associated with Cognitive Impairment and Elevated Phospholipase A2 Activity in Plasma of Mice

S. Smesny, M. Riva, P. Gass, 2021, Neuroscience.

Prostaglandin-mediated signaling in schizophrenia.

S. Smesny, 2004, International review of neurobiology.

The differential association between local neurotransmitter levels and whole‐brain resting‐state functional connectivity in two distinct cingulate cortex subregions

Meng Li, J. Reichenbach, G. Wagner, 2022, Human brain mapping.

Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level

Cedric E. Ginestet, Jennifer M. Coughlin, P. Renshaw, 2021, JAMA psychiatry.

Clinical trajectories in the ultra-high risk for psychosis population

S. Smesny, M. Nordentoft, A. Riecher-Rössler, 2018, Schizophrenia Research.

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION

I. Hickie, S. Smesny, M. Nordentoft, 2018, Schizophrenia Bulletin.

Phospholipase A2 activity is associated with structural brain changes in schizophrenia

Christian Gaser, Heinrich Sauer, Christoph Preul, 2010, NeuroImage.

Effects of olanzapine on 31P MRS metabolic markers in schizophrenia

J. Reichenbach, H. Sauer, S. Smesny, 2013, Human psychopharmacology.

Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis

Cedric E. Ginestet, Katharine N. Thakkar, P. Renshaw, 2023, Molecular Psychiatry.

Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naïve ultra-high-risk subjects and first-episode schizophrenia

J. Reichenbach, H. Sauer, S. Smesny, 2015, European Neuropsychopharmacology.

Frequency domains of resting state default mode network activity in schizophrenia

Christian Gaser, Jürgen R. Reichenbach, Heinrich Sauer, 2013, Psychiatry Research: Neuroimaging.

Resting state functional connectivity of the hippocampus along the anterior–posterior axis and its association with glutamatergic metabolism

Jürgen R. Reichenbach, Karl-Jürgen Bär, Stefan Smesny, 2016, Cortex.

Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia

Timm Rosburg, Heinrich Sauer, Stefan Smesny, 2005, Biological Psychiatry.

Cognitive function in euthymic bipolar disorder (BP I) patients with a history of psychotic symptoms vs. schizophrenia

H. Sauer, S. Smesny, I. Nenadić, 2015, Psychiatry Research.

Phospholipase A2 activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12

H. Sauer, S. Smesny, I. Nenadić, 2011, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Do neuroleptics alter the cerebral intracellular pH value in schizophrenics?—a 31P-MRS study on three different patient groups

H. Sauer, S. Riehemann, H. Volz, 2002, Psychiatry Research: Neuroimaging.

Critical Reappraisal of a Catechol-O-Methyltransferase Transversion Variant in Schizophrenia

S. Smesny, P. Sand, M. Domani, 2010, Biological Psychiatry.

Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Sumudu R. Mallawaarachchi, I. Hickie, S. Smesny, 2020, Schizophrenia Research.

Erythrocyte glutathione levels as long-term predictor of transition to psychosis

S. Smesny, P. McGorry, S. Lavoie, 2017, Translational Psychiatry.

[Repetitive transcranial magnetic stimulation (rTMS) in the acute and long-term therapy of refractory depression--a case report].

J. Liepert, H. Volz, S. Smesny, 2001, Der Nervenarzt.

The topical niacin sensitivity test: an inter- and intra-rater reliability study in healthy controls.

S. Smesny, P. McGorry, T. Proffitt, 2008, Prostaglandins, leukotrienes, and essential fatty acids.